At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 12, 2026 at 16:17 ET
ProMIS Neurosciences reported Q3 2026 net loss of $8.2M ($0.89 per share) and cash of $44.1M, reaffirming on-track unblinded 12-month topline data from the PRECISE-AD Phase 1b trial in Q1 2027. The filing is a routine quarterly update for a pre-revenue clinical-stage biotech with no consensus EPS or revenue to compare against.
- Cash of $44.1M as of September 30, 2026, expected to fund operations through 2027
- Net loss of $8.2M for Q3 2026 versus $11.6M in Q3 2025
- R&D expenses decreased 32% to $6.7M due to PRECISE-AD nearing completion
- PRECISE-AD unblinded 12-month topline data anticipated in Q1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access